Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

Kreutzer, Thomas C.; Alge, C. S.; Wolf, A. H.; Kook, Daniel; Burger, J.; Strauss, R.; Kunze, C.; Haritoglou, Christos; Kampik, Anselm and Priglinger, Siegfried (2008): Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. In: British Journal of Ophthalmology, Vol. 92, No. 3: pp. 351-355

Abstract

Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.Methods: A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.Results: Patients presented at a mean age of 69 years (range 44--86). Mean duration of symptoms was 40 weeks (range 1--300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) \textgreekmm, declining to 316 (41) \textgreekmm at 6 months.Conclusion: Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• Alliance/National Licence: This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
• Language: English